Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
41.12
+1.37 (3.45%)
Jul 30, 2026, 4:00 PM EDT - Market closed
Edgewise Therapeutics Employees
Edgewise Therapeutics had 154 employees as of March 31, 2026. The number of employees increased by 8 or 5.48% since the number was last reported on December 31, 2025.
Employees
154
Change
8
Growth
5.48%
Revenue / Employee
n/a
Profits / Employee
-$1,142,922
Market Cap
4.42B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 154 | 8 | 5.48% |
| Dec 31, 2025 | 146 | 36 | 32.73% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| ACADIA Pharmaceuticals | 798 |
| Denali Therapeutics | 507 |
| CRISPR Therapeutics AG | 393 |
| Dyne Therapeutics | 263 |
| Relay Therapeutics | 193 |
| Celcuity | 155 |
| Parabilis Medicines | 145 |
EWTX News
- 10 days ago - Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI - TheFly
- 17 days ago - Edgewise Therapeutics completes sale of sevasemten for up to $2.65B - TheFly
- 17 days ago - Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4 - TheFly
- 17 days ago - Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - PRNewsWire
- 21 days ago - Edgewise Therapeutics initiated with an Outperform at Oppenheimer - TheFly
- 24 days ago - Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim - TheFly
- 4 weeks ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 6 weeks ago - Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital - TheFly